Biosimilars still to make an impact in the UK
Given that the UK market shows high generic penetration, it might be expected to be just as attractive for biosimilar manufacturers. However, the biosimilars market remains small in the UK with the...
View ArticleBiosimilars in the EU – Payers are key to driving uptake…
Research from Datamonitor Healthcare has revealed that the UK lags behind some European countries in terms of biosimilars uptake, and there is significant variation in the uptake of different product...
View ArticlePfizer pays $17bn to buy Hospira: As seen in the Telegraph
Pfizer has struck a $17bn deal to buy smaller rival Hospira, it’s first major deal since their play for AstraZeneca collapsed last year. Pfizer had made some smaller acquisitions since walking away...
View ArticleEvolution of the Biosimilars Landscape
Approval of the US biosimilar approval pathway has coincided with increased Big Pharma activity and a surge in new Phase III clinical trials. 2014 was a standout year for innovator biologic approvals,...
View ArticleThe Evolving Landscape of Biosimilars
Significant progress has been made with biosimilars over the last five years. We’ve produced an infographic that will give you a quick insight into how the landscape has evolved and what the outlook...
View ArticleREPORT: The Evolving Landscape in Biosimilars
By purchasing our newest report you’ll be able to experience an in-depth tour of the current biosimilars market, how it’s evolved and how it will continue to develop. Features and Benefits: Determine...
View Article
